BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 15, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Sutent sunitinib: Phase III data

Data from the open-label Phase III SUN 1064 trial for first-line treatment of advanced HER2-negative breast cancer showed that Sutent plus Taxotere docetaxel missed the primary endpoint of significantly improving PFS vs. Taxotere alone. Last year,...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >